Literature DB >> 2143678

Analysis by DNA polymerase alpha activity of human breast tumour proliferation and the effect of endocrine therapy.

N G Coldham1, L C Lai, M J Reed, M W Ghilchik, N A Shaikh, V H James.   

Abstract

Cytosols of human breast tumours have been assayed for DNA dependent DNA polymerase alpha activity. DNA polymerase alpha activity in benign tumours was found to be significantly lower than in untreated malignant tumours. Biopsy samples removed surgically before and after endocrine therapy showed reduced DNA polymerase alpha activity in 6 out of 9 patients treated with 4-hydroxyandrostenedione, and in 6 out of 7 patients treated with MPA. DNA polymerase alpha activity in malignant breast tumours was higher in oestrogen receptor negative than oestrogen receptor positive tumours.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2143678      PMCID: PMC1971841          DOI: 10.1038/bjc.1990.273

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

1.  DNA polymerases of rabbit mammary gland: partial purification, characterization and changes in DNA polymerase activities as a function of physiological state.

Authors:  W Niedbalski; L Zwierzchowski; L D Wasilewska
Journal:  Int J Biochem       Date:  1986

Review 2.  Progestin action and progesterone receptor structure in human breast cancer: a review.

Authors:  K B Horwitz; L L Wei; S M Sedlacek; C N d'Arville
Journal:  Recent Prog Horm Res       Date:  1985

Review 3.  DNA polymerases in prokaryotes and eukaryotes: mode of action and biological implications.

Authors:  U Hübscher
Journal:  Experientia       Date:  1983-01-15

4.  Effects of estrogen and antiestrogen on DNA polymerase in human breast cancer.

Authors:  D P Edwards; S R Murthy; W L McGuire
Journal:  Cancer Res       Date:  1980-05       Impact factor: 12.701

5.  1. Estrogen antagonists. Aromatase inhibitors, their pharmacology and application.

Authors:  A M Brodie; W M Garrett; J R Hendrickson; C H Tsai-Morris; J G Williams
Journal:  J Steroid Biochem       Date:  1983-07       Impact factor: 4.292

6.  Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route.

Authors:  M Dowsett; P E Goss; T J Powles; G Hutchinson; A M Brodie; S L Jeffcoate; R C Coombes
Journal:  Cancer Res       Date:  1987-04-01       Impact factor: 12.701

7.  Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labeling study.

Authors:  J S Meyer; M U Prey; D S Babcock; R W McDivitt
Journal:  Lab Invest       Date:  1986-01       Impact factor: 5.662

8.  Semiautomated measurement of rapidly hydrolyzed DNA in the diagnosis of mammary carcinoma.

Authors:  A M Sincock
Journal:  Cancer       Date:  1986-01-01       Impact factor: 6.860

9.  Estrogen, androgen, glucocorticoid, and progesterone receptors in progestin-induced regression of human breast cancer.

Authors:  F A Teulings; H A van Gilse; M S Henkelman; H Portengen; J Alexieva-Figusch
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

10.  Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.

Authors:  M Izuo; Y Iino; K Endo
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.